{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 56,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide highlights consistent clinical activity across two study phases, culminating in a combined ORR of 33.3%.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/19",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.4,
        "y": 0.7
      },
      "kind": "callout",
      "text": "Total of 13/39 responses 33.3% ORR",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3fe6f14-38c3-468d-880e-3d940b26bb88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*De Braud et al AACR 2022\n# Lebbe et al ESMO 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7b72c30-1067-46ef-b2e6-f6667f46edf8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.82,
        "x": 0.09,
        "y": 0.305
      },
      "kind": "table",
      "text": "Study/Indication | Data Cutoff | ORR | DCR | DOR | Source\nPhase 1 (LXH254X2102*) | 9 Dec 2021 | 7/15 (46.7%) | 12/15 (80.0%) | 3.75 mo | AACR 2022\nPhase 2 (LXH254C12201#) | 4 July 2022 | 6/24 (25.0%) | 17/24 (70.8%) | NA | ESMO 2022",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d21e4af0-785a-464b-bbc4-e9f2aeb66ac5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Clinical activity of naporafenib + trametinib in NRASm melanoma at the likely Recommended Dose was reproducible across Phase 1 and Phase 2 studies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7dcfb337-8c04-44d5-bd76-3ac589b7d32b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "6bd374b8-14ec-4b50-9eb4-eb2e4705911e",
      "evidence": "table/data: Study/Indication | Data Cutoff | ORR | DCR | DOR | Source",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "0ba8dc28-f394-4539-9ceb-99555f1271c2",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the unmet needs and limitations of current treatments for NRASm metastatic melanoma.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    },
    {
      "to": 20,
      "from": 13,
      "beatId": "f286216e-8f02-4c67-ba26-139ada264780",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides evidence and proof of Erasca's pipeline and its potential effectiveness.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1dd29138-5e83-440f-a4ea-0cd29a31a0c3",
      "evidence": "The document highlights the limitations of current treatments and the potential benefits of Erasca's pipeline.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet needs in cancer treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}